{
    "nctId": "NCT06149377",
    "briefTitle": "Impact of a Predictive Model on Sentinel Lymph Node Biopsy in Initially Lymph Node-positive, HER2-positive Breast Cancer",
    "officialTitle": "Application of a Predictive Model on Sentinel Lymph Node Biopsy in Initially Lymph Node-positive, HER2-positive Breast Cancer After Neoadjuvant Systemic Therapy: a Multicenter Retrospective Study",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Sentinel Lymph Node",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 716,
    "primaryOutcomeMeasure": "Axillary pCR",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* histologically proven primary breast cancer without distant metastatic lesions,\n* HER2-positive status (defined as immunohistochemistry (IHC) of 3+ overexpression or 2+ expression, and a ratio of \u2265 2.0 by fluorescence in situ hybridization),\n* initial axillary lymph node-positive status confirmed using core- or fine-needle biopsy before NST,\n* a full course of standard neoadjuvant therapy before surgery\n* complete clinicopathological characteristics and treatment information.\n\nExclusion Criteria:\n\n* do not plan or are unable to operate;\n* with distant metastasis\n* do not accept full cycles or standard neoadjuvant systemic therapy\n* loss of clinicopathological characteristics and treatment information.\n* with serious cardiopulmonary diseases, uncontrolled infectious diseases and other non-tumor related diseases who could not tolerate comprehensive treatment such as surgery and chemotherapy",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}